Researchers have discovered a potential neuroimaging biomarker that could help personalize treatments for depression.
Lithium is a ‘gold standard’ drug for treating bipolar disorder, however not everyone responds in the same way. New research published in BioMed Central’s open access journal Biology of Mood & Anxiety Disorders finds that this is true at the levels of gene activation, especially in the activation or repression of genes which alter the level the apoptosis (programmed cell death).
The same gene variations that make it difficult to stop smoking also increase the likelihood that heavy smokers will respond to nicotine-replacement therapy and drugs that thwart cravings, a new study shows.
New research from the Royal College of Surgeons in Ireland (RCSI) published in Nature’s Neuropsychopharmacology has shown physical changes to exist in specific brain areas implicated in schizophrenia following the use of cannabis during adolescence. The research has shown how cannabis use during adolescence can interact with a gene, called the COMT gene, to cause physical changes in the brain.
Antidepressive drugs reduce the mortality rate of schizophrenic patients, while treatment with bensodiazepines greatly increases it, especially as regards suicide. Giving several antipsychotics simultaneously, however, seems to have no effect at all. This according to a new study examining different drug combinations administered to patients with schizophrenia.
New research from Yale could help explain why cocaine addiction, abuse and dependency is dramatically increased in people who began using the drug during their teenage years, as opposed to later in adulthood.
A new editorial released this week offers clarity and structure on confusing drug and alcohol addiction terminology for prescribers, users and regulators. “Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?” is published in the Journal of Psychopharmacology, the official journal of the British Association for Psychopharmacology, published by SAGE.
A new study published in the journal Molecular Psychiatry has identified that some antipsychotic drugs can have adverse side effects such as diabetes and obesity as they activate the TGFbeta pathway, a mechanism known to control cellular functions such as insulin production.
New research released this week by the University of Buffalo suggests smokers might have more success at kicking the habit if they start using smoking cessation medications, such as varenicline, for several weeks prior to their quit date. Findings showed that smokers who took the medication for four weeks prior to quitting were more likely to remain tobacco-free three months after the trail ended, compared to those who only took the drug for the regularly prescribed time frame of one week. The female participants also fared better in their quest to quit, with 67% remaining smoke free at the three month follow up.
A new report from psychiatrists at UT Southwestern has pointed to a correlation between low levels of vitamin D and depression. Researchers discovered that lower levels of vitamin D were apparent in people with current depressive symptoms, particularly those who had a history of depression. However, the researchers are yet to determine whether the low vitamin D levels contribute to depressive symptoms, or whether the depression contributes to lower levels of the vitamin.